Luminex Corporation Reports First Quarter 2013 Results GAINED FDA CLEARANCE FOR NOVEL GASTROINTESTINAL PATHOGEN PANEL PR Newswire AUSTIN, Texas, April 29, 2013 AUSTIN, Texas, April 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2013. Financial and operating highlights include the following: oConsolidated first quarter revenue was $53.2 million, a 9 percent increase over the first quarter of 2012 oConsolidated gross profit margin was 71 percent for the first quarter of 2013, compared to 69 percent for the first quarter of 2012 oNon-GAAP net income for the first quarter was $7.9 million or $0.19 per diluted share. This compares to non-GAAP net income of $6.6 million, or $0.15 per diluted share for the first quarter of 2012. GAAP net loss for the first quarter was $2.5 million, or ($0.06) per diluted share.after a charge of $7.0 million associated with finalizing the termination of our molecular distribution agreements. This compares to GAAP net income of $3.5 million, or $0.08 per diluted share in the first quarter of 2012 (see the reconciliation of GAAP to non-GAAP set forth on page 7) oReceived FDA clearance for the xTAG Gastrointestinal Pathogen Panel (xMAP® GPP™) on the LX200 system in January and on the MAGPIX system in April oSigned a collaboration and license agreement with Merck (NYSE: MRK) to develop a companion diagnostic that will help screen patients into Merck's lead investigational candidate drug study for Alzheimer's disease (AD) (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) "Our royalty revenue grew 23% while our total cumulative shipments of multiplexing analyzers expanded to almost 10,000 units, or 11% over the year ago period, both of which indicate the strong ongoing demand for our proprietary technology," said Patrick J. Balthrop, president and chief executive officer of Luminex. "Furthermore, the company's successful transition to a direct molecular diagnostic sales force, effective January 1, 2013, was an important step in our ability to directly control the growth of our assay revenues going forward. We now have direct coverage of our molecular diagnostic products in the U.S. and major markets internationally. The customer response has been very positive," added Balthrop. "In other strategic initiatives, we continue to make good progress with our unique sample to answer system, called Project ARIES, which we will be demonstrating to key opinion leaders at the upcoming Clinical Virology Symposium in Florida. "We continue to be pleased with the expansion of our product offerings in infectious disease and genetic testing, particularly with the recent FDA clearance of GPP running on MAGPIX, our lower cost multiplexing analyzer. With new assays like GPP and the exciting portfolio from Luminex Madison, we are positioned for continued growth," Balthrop concluded. REVENUE SUMMARY (in thousands, except percentages) Three Months Ended March 31, Variance 2013 2012 ($) (%) (unaudited) System sales $ 6,557 $ 6,998 $ (441) -6% Consumable sales 11,897 11,900 (3) 0% Royalty revenue 10,109 8,242 1,867 23% Assay revenue 18,324 17,297 1,027 6% All other revenue 6,313 4,290 2,023 47% $ 53,200 $ 48,727 $ 4,473 9% "We are pleased with the overall financial performance in the first quarter of 2013, as Luminex transitions to a direct molecular diagnostic salesforce and invests in exciting strategic programs, like Project ARIES," said Harriss T. Currie, senior vice president and chief financial officer. "As reviewed previously, operating expenses for the current quarter included a $7.0 million charge attributable to finalizing the termination of our molecular diagnostic distribution arrangements. If you exclude this charge, operating margin for the first quarter would be 10%. Investment in our new Project Aries system was robust during the quarter and added just over $3 million to R&D expenses for our ARP segment during the period." LUMINEX CORPORATION REPORTABLE SEGMENT HIGHLIGHTS (in thousands, except percentages) Three Months Ended March 31, Variance 2013 2012 ($) (%) (unaudited) Revenue Technology and strategic partnerships $ 31,869 $ 30,209 $ 1,660 5% Assays and related products 21,331 18,518 2,813 15% Total Revenue 53,200 48,727 4,473 9% Operating income (loss) Technology and strategic partnerships 7,681 7,230 451 6% Assays and related products (9,233) (1,622) (7,611) -469% Total Operating income (loss) (1,552) 5,608 (7,160) -128% FINANCIAL OUTLOOK AND GUIDANCE The Company reaffirms its 2013 annual revenue guidance of between $220 and $230 million. CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013, on Monday, April 29, 2013, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link. Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com. Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base of multiplexing systems; our efforts to sell our molecular diagnostic products directly to end users; the development progress of our pipeline products, including Project Aries, NeoPlex4 and the NeoPlex System; anticipated FDA clearance of our products, including NeoPlex4 and the NeoPlex system and Project Aries; market acceptance of our products, including Gastrointestinal Pathogen Panel, Cystic Fibrosis, RVP FAST, 2D6 and other genetic testing products; our collaboration with Merck regarding an Alzheimer's diagnostic assay; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2013 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, our ability to sell products directly to end users, our ability to satisfy market needs with products that we sell, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements, including the financial guidance and 2013 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Contacts: Harriss T. Currie Matthew Scalo Sr. Vice President, Finance and Chief Sr. Director, Investor Financial Officer Relations 512-219-8020 512-219-8020 firstname.lastname@example.org email@example.com LUMINEX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) March 31, December 31, 2013 2012 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 54,289 $ 42,789 Short-term investments 6,599 13,607 Accounts receivable, net 25,127 33,273 Inventories, net 32,332 29,937 Deferred income taxes 5,818 6,148 Prepaids and other 4,693 4,388 Total current assets 128,858 130,142 Property and equipment, net 26,588 26,229 Intangible assets, net 64,193 65,218 Deferred income taxes 12,812 12,819 Long-term investments - 3,000 Goodwill 51,139 51,128 Other 9,286 8,463 Total assets $ 292,876 $ 296,999 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,924 $ 9,650 Accrued liabilities 16,397 12,690 Deferred revenue 4,524 4,134 Current portion of long term debt 1,409 1,138 Total current liabilities 30,254 27,612 Long-term debt 1,403 1,702 Deferred revenue 2,791 2,933 Other 5,113 5,085 Total liabilities 39,561 37,332 Stockholders' equity: Common stock 41 41 Additional paid-in capital 289,662 293,392 Accumulated other comprehensive gain 990 1,101 Accumulated deficit (37,378) (34,867) Total stockholders' equity 253,315 259,667 Total liabilities and stockholders' equity $ 292,876 $ 296,999 LUMINEX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three Months Ended March 31, 2013 2012 (unaudited) Revenue $ 53,200 $ 48,727 Cost of revenue 15,243 14,967 Gross profit 37,957 33,760 Operating expenses: Research and development 12,714 10,137 Selling, general and administrative 25,766 16,915 Amortization of acquired intangible assets 1,029 1,100 Total operating expenses 39,509 28,152 (Loss) income from operations (1,552) 5,608 Interest expense from long-term debt (28) (59) Other income, net (7) 57 (Loss) income before income taxes (1,587) 5,606 Income taxes (924) (2,079) Net (loss) income $ (2,511) $ 3,527 Net (loss) income per share, basic $ (0.06) $ 0.09 Shares used in computing net (loss) income per share, 40,887 40,919 basic Net (loss) income per share, diluted $ (0.06) $ 0.08 Shares used in computing net (loss) income per share, 40,887 42,805 diluted LUMINEX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Three Months Ended March 31, 2012 2011 (unaudited) Cash flows from operating activities: Net (loss) income $ (2,511) $ 3,527 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 3,804 3,522 Stock-based compensation 2,432 2,643 Deferred income tax expense 700 553 Excess income tax expense (benefit) from employee 274 (297) stock-based awards Loss on disposal of assets 18 - Other 198 232 Changes in operating assets and liabilities: Accounts receivable, net 8,095 (4,013) Inventories, net (2,404) 133 Other assets (896) 40 Accounts payable (1,731) (486) Accrued liabilities 1,777 (6,026) Deferred revenue 263 143 Net cash provided by (used in) operating activities 10,019 (29) Cash flows from investing activities: Purchases of available-for-sale securities (2,995) (8,999) Sales and maturities of available-for-sale securities 13,033 8,515 Purchase of property and equipment (2,791) (1,596) Proceeds from sale of assets 31 - Acquired technology rights (930) - Net cash provided by (used in) investing activities 6,348 (2,080) Cash flows from financing activities: Proceeds from employee stock plans and issuance of 1,401 657 common stock Payments for stock repurchases (5,775) (5,448) Excess income tax (expense) benefit from employee (274) 297 stock-based awards Net cash used in financing activities (4,648) (4,494) Effect of foreign currency exchange rate on cash (219) 151 Change in cash and cash equivalents 11,500 (6,452) Cash and cash equivalents, beginning of period 42,789 58,282 Cash and cash equivalents, end of period $ 54,289 $ 51,830 LUMINEX CORPORATION NON-GAAP RECONCILIATION (in thousands) Three Months Ended March 31, 2013 2012 (unaudited) Net loss $ (2,511) $ 3,527 Stock-based compensation 2,432 2,643 Amortization of acquired intangible assets 1,029 1,100 Costs associated with legal proceedings 113 - Resolution of molecular diagnostic distribution agreements 7,000 - Severance costs 330 71 Income tax effect of above adjusting items (535) (735) Adjusted net income $ 7,858 $ 6,606 Adjusted net income per share, basic $ 0.19 $ 0.16 Shares used in computing adjusted net income per share, 40,887 40,919 basic Adjusted net income per share, diluted $ 0.19 $ 0.15 Shares used in computing adjusted net income per share, 41,750 42,805 diluted The Company makes reference in this release to "non-GAAP net income" which excludes the impact of certain recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company's ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company's past financial performance and prospects for the future. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP. SOURCE Luminex Corporation Website: http://www.luminexcorp.com
Luminex Corporation Reports First Quarter 2013 Results
Press spacebar to pause and continue. Press esc to stop.